Exagen (XGN) Earnings Analysis

Exagen (XGN) has no confirmed upcoming earnings date. Last quarter (2026-05-11) it beat with EPS -0.17 USD vs -0.24 USD est (+29.2%). It has beaten estimates in 5/5 recent quarters (100%). Trailing P/E -5.49.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does XGN next report earnings?

No confirmed upcoming earnings date is currently scheduled for XGN. This page updates as the calendar is published.

XGN earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-11-0.17 USD-0.24 USD+29.2%Beat
2026-03-10-0.2 USD-0.2 USD0%Beat
2025-05-05-0.2 USD-0.2 USD0%Beat
2025-03-11-0.2 USD-0.27 USD+25.9%Beat
2024-08-05-0.16 USD-0.36 USD+55.6%Beat

Beat rate: 5/5 (100%) over reported quarters with consensus data.

XGN valuation and analyst view

Trailing P/E-5.49
Trailing EPS-0.84536 USD
Price / book8.17
Dividend yield0.00%
Market cap0.12B
Analyst consensusBuy (10 buy / 0 hold / 0 sell)
Avg price target8 USD

Related research pages

Frequently asked questions

When is Exagen (XGN)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for XGN. This page updates as the calendar is published.

Did XGN beat earnings last quarter?

In its 2026-05-11 report, XGN posted EPS of -0.17 USD versus a -0.24 USD estimate — a beat of 29.2%.

What is XGN's earnings track record?

Over the last 5 reported quarters with consensus data, XGN beat estimates 5 times (100%).

What is XGN's current P/E ratio and EPS?

XGN trades at a trailing P/E of -5.49 on trailing EPS of -0.8453574737401979 USD.

What do analysts rate XGN?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 8 USD.